DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
According to a preliminary amendment filed on Oct. 17, 2024, the applicants have canceled claims 1-53 and furthermore, have added new claims 54-59.
Claims 54-59 are pending in the application.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 54 and 55 are rejected under 35 U.S.C. 102(a) (1) as being clearly anticipated by Powers (US 2006/0173183 A1, cited on applicant’s form 1449).
Power discloses multicyclic bis-amide MMP inhibitors. The compound disclosed in example 2106 (see paragraph [700] on page 116 clearly anticipates the instant compound of formula (5-4).
Allowable Subject Matter
The following is a statement of reasons for the indication of allowable subject matter: Claims 56-59 are allowed since the instant compounds are neither disclosed nor obvious over the prior art. In the prior art, Power (US 2006/1`73183 A1, cited on applicant’s form 1449) discloses 1,2,4- oxadiazole compound in example 2106 (see page 116) which is closely related to instant compound of formula (15-2). However, this compound differs from the compound of formula (15-2) by having 1,2,4-oxadiazole substituted with an oxo group instead of an ethyl group. Furthermore, there is no teaching, suggestion or motivation in the prior art to modify the compound disclosed by Powers to prepare instant compound of formula (15-2).
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Prosecution Insights